What is Urokinase?
Urokinase (also called urokinase-type plasminogen activator, or uPA) is a serine protease enzyme that plays a central role in the breakdown of blood clots (fibrinolysis). It converts plasminogen (an inactive zymogen) into plasmin, the active enzyme that degrades fibrin-the main protein component of blood clots.
Discovered: Initially isolated from human urine (hence the name).
Produced By: Kidney epithelial cells, macrophages, fibroblasts, and other tissues.
Molecular Weight: ~54 kDa (high molecular weight form), ~33 kDa (low molecular weight form).
Enzyme Class: EC 3.4.21.73
Mechanism of Action
- Urokinase binds to plasminogen, cleaving a specific peptide bond.
- This converts plasminogen into plasmin.
- Plasmin degrades fibrin clots into soluble fragments, effectively dissolving thrombi.
Unlike tissue plasminogen activator (tPA), urokinase does not require fibrin for activation, making it more general in its plasminogen activation.
Clinical Applications
Urokinase is used therapeutically as a thrombolytic agent, especially in conditions where blood clots obstruct critical vessels:
1. Pulmonary Embolism (PE)
- Administered via intravenous or catheter-directed infusion.
- Rapidly dissolves pulmonary arterial clots.
2. Deep Vein Thrombosis (DVT)
- Used to reduce clot burden and restore venous flow.
- Helps prevent long-term complications like post-thrombotic syndrome.
3. Myocardial Infarction (MI)
- Less commonly used today for acute coronary syndromes (tPA is preferred), but still relevant in certain settings.
4. Catheter Clearance
- Marketed as urokinase lock solutions (e.g., Abbokinase®) to clear clotted central venous catheters.
5. Peripheral Arterial Occlusion
- Used in intra-arterial thrombolysis to restore blood flow to limbs.
Forms & Administration
| Formulation | Route | Use |
|---|---|---|
| Urokinase (IV infusion) | Intravenous | Systemic thrombolysis |
| Catheter-directed urokinase | Intra-arterial or intravascular | Targeted clot dissolution |
| Urokinase lock | Intracatheter | Central line patency |
Safety & Side Effects
Like all thrombolytics, urokinase carries a risk of bleeding, especially:
- Intracranial hemorrhage
- Gastrointestinal bleeding
- Hematuria (blood in urine)
Contraindications include:
- Recent surgery or trauma
- Active bleeding
- History of hemorrhagic stroke
- Uncontrolled hypertension
Monitoring: Patients require close monitoring of clotting parameters and signs of bleeding.
Urokinase vs. Other Thrombolytics
| Feature | Urokinase | tPA (Alteplase) | Streptokinase |
|---|---|---|---|
| Source | Human cells | Recombinant human protein | Bacterial (Streptococcus) |
| Fibrin specificity | Low | High | Low |
| Immunogenicity | Low | Very low | High (can induce allergic reactions) |
| Clinical use | PE, DVT, catheter clearance | Stroke, MI, PE | Rarely used today |
| Cost | Moderate | High | Low |
Market Status & Regulatory Info
Trade Names: Abbokinase®, Kinlytic® (in the US)
FDA Status: Approved for lysis of pulmonary embolism and catheter occlusions.
Global Use: Used in Europe, Asia, and the Americas in hospital-based thrombolytic therapy.
Emerging Research & Applications
Cancer: uPA is involved in cancer cell migration and invasion. High uPA expression correlates with poor prognosis in breast and other cancers.
Wound Healing: Plays a role in tissue remodeling and angiogenesis.
Neuroscience: Studied for its effects on neural plasticity and regeneration post-stroke.
Summary Table
| Aspect | Details |
|---|---|
| Type | Serine protease |
| Primary Action | Converts plasminogen to plasmin |
| Main Uses | Thrombolysis in PE, DVT, catheter occlusion |
| Advantages | Low immunogenicity, effective clot dissolution |
| Risks | Bleeding, especially in high-risk patients |
| Research Areas | Oncology, neuroscience, regenerative medicine |






